07:56 AM EST, 01/13/2026 (MT Newswires) -- XTL Biopharmaceuticals (XTLB) said Wednesday it will acquire an 85% stake in NeuroNOS, a subsidiary of Beyond Air ( XAIR ) .

Under the agreement, the company said it will pay $1 million in cash, 19.9% of its issued share capital, and make milestone-based payments of up to $32.5 million, including $5.5 million tied to clinical development and $26 million linked to commercial sales targets.

The company said NeuroNOS, led by founder Professor Haitham Amal and supported by Nobel Laureates Dan Shechtman and Roger Kornberg, will become its flagship platform for autism and neuro-oncology therapeutics.

Shares of Beyond Air ( XAIR ) were up more than 20% in Tuesday's premarket activity.